Form 4: PTC Therapeutics CEO Matthew Klein Reports Stock Sale to Cover Tax Obligations
SEC Form 4 Filing
CEO Matthew Klein sold 2,804 shares of PTC Therapeutics stock to cover tax obligations related to RSU vesting.
Summary
- On April 22, 2025, Matthew B. Klein, CEO of PTC Therapeutics, sold 2,804 shares of common stock at a price of $48.736 per share.
- The sale was executed to cover tax withholding obligations related to the vesting of 6,500 Restricted Stock Units (RSUs) from a grant made on April 18, 2023.
- Following the transaction, Klein directly owns 273,234 shares of PTC Therapeutics common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as the transaction is a routine sale to cover tax obligations.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. It is common for executives to sell shares to cover taxes when RSUs vest.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 04/18/2023 | Date of RSU grant (26,000 RSUs) |
| 04/22/2025 | Date of stock sale (2,804 shares) |
| 04/24/2025 | Date of signature on the Form 4 filing |
Keywords
PTC Therapeutics, Matthew Klein, stock sale, Form 4, RSU vesting, tax obligations, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.